Stock NGM NGM BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NGM Biopharmaceuticals, Inc.

Equities

NGM

US62921N1054

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 05/04/2024 am IST 		5-day change 1st Jan Change
1.54 USD -1.28% Intraday chart for NGM Biopharmaceuticals, Inc. -.--% +79.28%
05/04 NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index CI
05/04 The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2026
Capitalization 1 1,221 2,090 1,376 410.3 71.05 128.5
Enterprise Value (EV) 1 975.6 1,943 1,224 336.8 15.24 128.5
P/E ratio -21.8 x -20.2 x -11.4 x -2.47 x -0.5 x -
Yield - - - - - -
Capitalization / Revenue 1,17,94,185 x 2,39,24,953 x 1,76,70,680 x 74,14,474 x 1,60,86,172 x -
EV / Revenue 1,17,94,183 x 2,39,24,952 x 1,76,70,678 x 74,14,473 x 1,60,86,159 x -
EV / EBITDA -2,92,61,216 x -2,14,87,645 x -1,20,08,339 x -25,29,159 x -4,70,718 x -
EV / FCF -2,73,42,920 x -2,44,83,457 x -1,83,71,013 x -28,04,330 x -5,32,412 x -
FCF Yield -0% -0% -0% -0% -0% -
Price to Book - - - - - -
Nbr of stocks (in thousands) 66,047 68,997 77,709 81,726 82,716 83,462
Reference price 2 18.49 30.30 17.71 5.020 0.8590 1.540
Announcement Date 17/03/20 04/03/21 01/03/22 28/02/23 11/03/24 -
1USD in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2026
Net sales 103.5 87.37 77.88 55.33 4.417 -
EBITDA -41.74 -97.28 -114.6 -162.2 -150.9 -
EBIT -49.34 -103.8 -120.3 -166.2 -151.5 -
Operating Margin -47.65% -118.85% -154.51% -300.45% -3,429.09% -
Earnings before Tax (EBT) -42.8 -102.5 -120.3 -162.7 -142.4 -
Net income -42.8 -102.5 -120.3 -162.7 -142.4 -
Net margin -41.33% -117.3% -154.51% -293.98% -3,223.34% -
EPS -0.8500 -1.500 -1.560 -2.030 -1.730 -
Free Cash Flow -44.66 -85.38 -74.91 -146.3 -133.5 -
FCF margin -43.13% -97.72% -96.19% -264.39% -3,021.37% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/03/20 04/03/21 01/03/22 28/02/23 11/03/24 -
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2026
Net Debt - - - - - -
Net Cash position 246 147 152 73.5 55.8 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow -44.7 -85.4 -74.9 -146 -133 -
ROE (net income / shareholders' equity) - - - - -69.8% -
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 3.49 1.88 1.68 1.86 1.25 -
Capex / Sales 3.37% 2.15% 2.16% 3.36% 28.35% -
Announcement Date 17/03/20 04/03/21 01/03/22 28/02/23 11/03/24 -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NGM BIOPHARMACEUTICALS, INC. Stock NGM Biopharmaceuticals, Inc.
+79.28% 129M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 101B
ARGENX SE Stock argenx SE
+5.71% 23.07B
BIONTECH SE Stock BioNTech SE
-12.60% 22.23B
GENMAB A/S Stock Genmab A/S
-9.70% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NGM Stock
  4. Financials NGM Biopharmaceuticals, Inc.